v3.0.7
Please consider this website is continuously evolving and still under development
to harmonize automatic data extraction and integrate manual data annotation.
Column | Value |
---|---|
Trial registration number | EUCTR2020-001656-18-NO |
Full text link
Last imported at : Nov. 5, 2021, 1:30 p.m. Source : EU Clinical Trials Register |
https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001656-18/NO |
First author
Last imported at : Nov. 5, 2021, 1:30 p.m. Source : EU Clinical Trials Register |
|
Contact
Last imported at : Nov. 5, 2021, 1:30 p.m. Source : EU Clinical Trials Register |
cbuskop@ous-hf.no |
Registration date
Last imported at : Nov. 5, 2021, 1:30 p.m. Source : EU Clinical Trials Register |
2020-04-24 |
Recruitment status
Last imported at : Nov. 5, 2021, 1:30 p.m. Source : EU Clinical Trials Register |
Recruiting |
Study design
Last imported at : Nov. 5, 2021, 1:30 p.m. Source : EU Clinical Trials Register |
RCT |
Allocation
Last imported at : Nov. 5, 2021, 1:30 p.m. Source : EU Clinical Trials Register |
Randomized |
Design
Last imported at : Nov. 5, 2021, 1:30 p.m. Source : EU Clinical Trials Register |
Parallel |
Masking
Last imported at : Nov. 5, 2021, 1:30 p.m. Source : EU Clinical Trials Register |
Blind label |
Center
Last imported at : Nov. 5, 2021, 1:30 p.m. Source : EU Clinical Trials Register |
single-center |
Study aim
Last imported at : Nov. 5, 2021, 1:30 p.m. Source : EU Clinical Trials Register |
Treatment |
Inclusion criteria
Last imported at : Nov. 5, 2021, 1:30 p.m. Source : EU Clinical Trials Register |
All criteria must apply Patients ≥ 18 years of age at the time of inclusion and who are confirmed, suspected or probable cases of covid-19 based on WHO definitions and SpO2 <90% after 3 minutes 10 cm H2O PEEP + 100% O2 and who are treated by a physician who have specifically undergone formal training in pre-hospital INO administration and the present protocol. |
Exclusion criteria
Last imported at : Nov. 5, 2021, 1:30 p.m. Source : EU Clinical Trials Register |
Only one criterion needs to apply for exclusion: 1. Patients who after 3 mins of ventilation with 10 cm H2O PEEP + 100% O2 i.e. at time of allocation (t0), have a SpO2 <50%, or a reliable SpO2 is impossible to obtain 2. Patients in severe kidney failure or dialysis, 3. Known or suspected pregnancy based on information on the time of inclusion. 4. Hypersensitivity to the active substance (NO) or to the excipient (N2) 5. Cardiac arrest 6. Patient in prison or custody by police 7. Staff present in treatment situation known to be pregnant 8. Any reason why, in the opinion of the treating physician, it is probably in the best interest of the patient not to participate in the trial. Female participants under the age of 50 years will be asked explicitly about possible pregnancy. If this cannot be obtained from the patient, next of kin will be asked if present. Information regarding exclusion criteria 2, 3 and 4 will be obtained from bystanders, often relatives or friends present at time of inclusion. If no clear information is available, the physicians shall include or exclude based on his/her best judgment at the time of inclusion. |
Number of arms
Last imported at : Nov. 5, 2021, 1:30 p.m. Source : EU Clinical Trials Register |
2 |
Funding
Last imported at : Nov. 5, 2021, 1:30 p.m. Source : EU Clinical Trials Register |
Oslo University Hospital |
Inclusion age min
Last imported at : Nov. 5, 2021, 1:30 p.m. Source : EU Clinical Trials Register |
18 |
Inclusion age max
Last imported at : Nov. 5, 2021, 1:30 p.m. Source : EU Clinical Trials Register |
100 |
Countries
Last imported at : Nov. 5, 2021, 1:30 p.m. Source : EU Clinical Trials Register |
Norway |
Type of patients
Last imported at : Nov. 5, 2021, 1:30 p.m. Source : EU Clinical Trials Register |
Severe/critical disease at enrollment |
Severity scale
Last imported at : Nov. 5, 2021, 1:30 p.m. Source : EU Clinical Trials Register |
7: Severe/critical disease at enrollment |
Total sample size
Last imported at : Nov. 5, 2021, 1:30 p.m. Source : EU Clinical Trials Register |
54 |
primary outcome
Last imported at : Nov. 5, 2021, 1:30 p.m. Source : EU Clinical Trials Register |
The primary outcome measure is the change in SpO2, and the null hypothesis is that there is no difference in the change in SpO2 following initiation of INO |
Notes
Last imported at : Nov. 5, 2021, 1:30 p.m. Source : EU Clinical Trials Register |
Declared number of arm (2.0) differs from found arms (1.0) |
Phase
Last imported at : Nov. 5, 2021, 1:30 p.m. Source : EU Clinical Trials Register |
Phase 2 |
Arms
Last imported at : Nov. 5, 2021, 1:30 p.m. Source : EU Clinical Trials Register |
[{"arm_notes": "", "treatment_id": 890, "treatment_name": "Nitric oxide gas", "treatment_type": "Gas inhalation", "pharmacological_treatment": "Non pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}] |